Phibro Animal Health Corporation
corporate_fare Company Profile
Phibro Animal Health Corporation (NASDAQ:PAHC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for PAHC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for PAHC spans 8-K, 10-K, SCHEDULE 13D/A, 10-Q.
Recent high-impact activity:
- Phibro Q1 Sales Rise 6% to $386.8M, FY2027 Guidance Held
- Phibro Sets FY2027 Targets: $1.55B-$1.60B Sales, $258M-$268M Adjusted EBITDA; Chicago Heights Plant to Close
- Phibro Animal Health Posts Record FY2026 Sales, Guides FY2027 Above Consensus
- Phibro FY2026: Net Income Doubles to $99.7M on Zoetis MFA Integration; Chicago Heights Plant to Close
- Phibro Animal Health Appoints Daniel Bendheim as CEO, Grants Performance-Based RSUs with Aggressive Stock Price Targets
Financial Snapshot
Short Interest & Short Volume
6.42 days to coverFINRA reported short interest of 1,019,391 shares in PAHC as of the October 30, 2026 settlement, a 1.3% decrease from the prior period — about 6.4 days to cover at its recent average daily volume. On November 19, 2026, 45.8% of PAHC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.